A Phase I Dose Escalation Study of RAD001 [everolimus] Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 20 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 May 2013 Planned end date changed from 1 Jul 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 27 Apr 2012 Planned End Date 1 Jul 2013 added as reported by ClinicalTrials.gov.